hotspot -WSS

hotspot

author：comprehensive 2025-10-02 09:21:52 - browse：92279

LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday.

The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday. The Calliditas board has unanimously recommended that shareholders accept the offer, the company said, adding that it “aims to realize the benefits of being part of a larger platform” by being acquired.

Calliditas has an approved drug on the U.S. market called Tarpeyo, which treats a kidney disease called IgA nephropathy. The condition has in recent years attracted interest from a number of pharma companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Vertex cell therapy lets patients with type 1 diabetes stop insulin

WSS

Lupron, used to halt puberty in children, may cause lasting health problems

Beware reading your test results before your doctor does

UpToDate has a racism problem: Dr. Stanley Goldfarb

Use doctors trained outside the U.S. to ease the physician shortage

'Screen and refer' systems are hurting patients

Biden declares emergency in flood

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Apple is now the first public company to be valued at $3 trillion

Security flaws in third

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Lupron, used to halt puberty in children, may cause lasting health problems

Guidelines to prevent youth baseball injuries need more muscle

The wait for US passports is creating travel purgatory and snarling summer plans

DIEP, the 'gold standard' of breast reconstruction, is under threat

A letter from the executive editor: The 2023 STATUS List

Wildfire smoke exposes gaps in outdoor worker protections

Vertex cell therapy lets patients with type 1 diabetes stop insulin

knowledge

Medicare wants to send $9 billion to 340B hospitals

Parents surprise family after baby discharged from NICU after 170 days

See Ryan Reynolds, Hugh Jackman suited up in 1st look at 'Deadpool 3': Photo

Medicare wants to send $9 billion to 340B hospitals

US sending controversial cluster munitions to Ukraine until other ammo is ready: Kirby

Dexcom's push to bring CGM to type 2 diabetes patients

focus

explore

Wikipedia

hotspot